ClinicalTrials.gg
RecruitingNCT07157696HOME- OxygenUpdated Oct 8, 2026

Advanced Respiratory Monitoring and Oxygen Therapy in Chronically Ill Patients With Acute Respiratory Failure

An interventional study of High-Flow Nasal Cannula (HFNC) Oxygen Therapy and Oxygen therapy in Chronic Respiratory Failure, Cardiac Disease, Pulmonary Disease and Acute Respiratory Failure (ARF), sponsored by Università degli Studi di Ferrara. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Università degli Studi di Ferrara · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 8, 2026Now RecruitingFirst site in Italy+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Heart Diseases with a site in Italy — 31 open to participants now, 40 under way, 4 of them phase 3. Heart Diseases · Italy.

Planned enrollment
63rd of 66
16 · median 444
Started
2025
with 8 others
No phase
31 of 102
13 open now
Primary completion
2026-12
later than 14 of 39 live
Registered
92nd of 102
by date

Among the 102 studies in Heart Diseases with a site in Italy, this one is the 63rd largest by planned enrollment of the 66 interventional ones that give a count, is one of 9 that started in 2025, is one of 31 with no phase, reaches primary completion later than 14 of the 39 other live ones, and was the 92nd registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

31 of the 102 studies in Heart Diseases with a site in Italy are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Heart Diseases with a site in Italy, or all of them as a file.
02

Study summary

This study is testing whether a new type of home oxygen therapy, called high-flow nasal cannula (HFNC), can improve breathing comfort and quality of life for people with long-term lung or heart conditions who need oxygen after leaving the hospital.

HFNC delivers warm, humidified oxygen at higher flow rates than standard oxygen therapy, which may reduce shortness of breath, improve sleep, and make daily activities easier. The therapy will be provided using the myAirvo™3 device, which also allows doctors to check patients' oxygen levels, heart rate, and symptoms remotely. All patients will also wear a small device (RootiREX) to monitor heart rhythm, sleep quality, and detect breathing pauses at night.

Participants will try both treatments - HFNC and standard oxygen therapy - for short periods, in random order, so that researchers can directly compare the effects within the same patient. Each treatment period will last two weeks, with a short break in between.

The main goal of the study is to see whether HFNC reduces shortness of breath (measured by the modified Medical Research Council scale). Other outcomes include comfort, sleep quality, quality of life, oxygen levels, and how well patients are able to use the devices at home.

The study will last six weeks in total for each participant. Researchers expect that HFNC will improve breathing comfort, stabilize oxygen levels, and reduce the need for hospital visits during this time.

03

Conditions studied

  • Chronic Respiratory Failure
  • Cardiac Disease, Pulmonary Disease
  • Acute Respiratory Failure (ARF)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with chronic respiratory (e.g., , interstitial lung disease) and/or cardiac disease (e.g., heart failure),
  • Clinical indication for long-term oxygen therapy,
  • Capability to manage home-based devices independently or with caregiver assistance
  • Signed

Exclusion criteria

Exclusion Criteria:

  • \< 3 months
  • Inability to comply with home follow-up procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    High flow nasal cannulae treatment

    Participants assigned to this arm will receive home-based high-flow nasal cannula (HFNC) oxygen therapy using the myAirvo™3 device. The device delivers warm, humidified air with supplemental oxygen at a flow rate of ≥30 liters per minute, set at 37°C. Oxygen will be adjusted to maintain blood oxygen saturation (SpO₂) at or above 92%. • Group HFNC will receive HFNC during weeks 1-2, followed by a 2-day washout period, then low-flow oxygen during weeks 3-4, followed by a second 2-day washout period, and will resume HFNC during weeks 5-6

    Device: High-Flow Nasal Cannula (HFNC) Oxygen Therapy · Device: Oxygen therapy

  • Active comparator
    Oxygen low therapy

    Participants assigned to this arm will receive standard long-term oxygen therapy delivered by a conventional low-flow oxygen device. Oxygen will be titrated to maintain blood oxygen saturation (SpO₂) at or above 92%. • Group low flow oxygen will receive low-flow oxygen during weeks 1-2, followed by a 2-day washout period, then HFNC during weeks 3-4, followed by a second 2-day washout period, and will resume low-flow oxygen during weeks 5-6.

    Device: High-Flow Nasal Cannula (HFNC) Oxygen Therapy · Device: Oxygen therapy

Interventions

  • DeviceHigh-Flow Nasal Cannula (HFNC) Oxygen Therapy

    Type: Device / Procedure Description: Humidified high-flow nasal cannula oxygen therapy delivered via a home device. Provides warmed (37°C), humidified air and supplemental oxygen at ≥30 L/min, titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use the device for ≥8 hours per day, preferably overnight. Special Features: Integrated remote monitoring system that automatically records flow, FiO₂, SpO₂, heart rate, and usage time, transmitting data to a secure cloud platform for clinical follow-up.

  • DeviceOxygen therapy

    Type: Device / Procedure Description: Standard long-term oxygen therapy delivered through conventional low-flow systems (e.g., nasal cannula or mask). Oxygen is titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use oxygen for ≥8 hours per day, preferably overnight. Special Features: No humidification, high-flow delivery, or remote monitoring capabilities.

06

What researchers measure

Primary outcomes

  1. dyspnea modification

    Change from the enrollment in the study to 6 weeks in dyspnea level measured by the modified Medical Research Council (mMRC) scale

    Time frame: Change from the enrollment in the study to 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Savino SPADARO
    Ferrara, Italy 44121, Italy
    Recruiting
08

References and documents

Publications

  • Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T, Tokioka F, Chohnabayashi N, Watanabe A, Sato S, Tomii K. Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial. Ann Am Thorac Soc. 2018 Apr;15(4):432-439. doi: 10.1513/AnnalsATS.201706-425OC. PubMed 29283682 ↗
  • Weinreich UM, Burchardt C, Huremovic J. The effect of domiciliary high flow nasal cannula treatment on dyspnea and walking distance in patients with interstitial lung disease - A pilot study. Chron Respir Dis. 2022 Jan-Dec;19:14799731221137085. doi: 10.1177/14799731221137085. PubMed 36366859 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 13 months is below that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Nov 2025, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 5, 2025
StartActual
Nov 5, 2025was Oct 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 30, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added — first site in Italy
Show site
  • Savino SPADARO · Ferrara, Italy
Oct 8, 2026
Start date
Oct 3, 2025→Nov 5, 2025 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Italy
    Show site
    • Savino SPADARO · Ferrara, Italy
    Start date Oct 3, 2025→Nov 5, 2025 (now actual)
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07157696
Lead sponsor
Università degli Studi di Ferrara
Collaborators
S. Anna Hospital, University Hospital of Ferrara
Responsible party
Savino Spadaro (Professor, Università degli Studi di Ferrara) — Principal investigator
First posted
Sep 5, 2025
Start date
Nov 5, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

Savino Spadaro, Associate professor
Contact
spdsvn@unife.it
+393894841243

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion